Rx License-Rx

TAB-5033

Oxynitidine Derivatives as Tyrosyl DNA Phosphodiesterase (TDP) Inhibitors and Radiosensitizers

Summary: The National Cancer Institute (NCI) is actively seeking potential licensees and/or co-development research collaboration partners interested in further developing this family of oxynitidine derivatives as tyrosyl-DNA phosphodiesterase 1 (TDP1) inhibitors and radiosensitizers for the treatment of cancer. Description of Technology: Tyrosyl-DNA phosphodiesterase 1 (TDP1) is an enzyme that promotes the repair of DNA damage caused by common anti-cancer interventions, such as ionizing radiation (IR) and topoisomerase 1 (TOP1) chemotherapy. This enzyme plays a critical role in repairing the trapped DNA cleavage complexes induced by clinically used TOP1 chemotherapy (such as irinotecan and topotecan). TDP1 also plays a regulatory role in non-homologous end joining (NHEJ) in the repair of DNA double-strand breaks and damage caused by ionizing radiation. In both cases, this leads to a diminished therapeutic effect of the intervention...

Intelligence Memo

Owner: National Institutes of Health

Core category: Therapeutics

Therapeutic area: Oncology

Indication: Oncology

Modality: Biologic

Focus tags: Oncology

Technology tags: Biologic, Small Molecule

Mechanism:

Development stage: Preclinical

Patent status: Expired; Pending

Availability: Available for license

Plain-English Licensing Breakdown

This is a license opportunity for a therapeutic asset or drug-enabling technology in Oncology. In plain English, the buyer would be licensing science that could become a treatment program, usually after more validation. The current package appears to be preclinical and is associated with National Institutes of Health. The practical first use case is Oncology. Public description: Summary: The National Cancer Institute (NCI) is actively seeking potential licensees and/or co-development research collaboration partners interested in further developing this family of oxynitidine derivatives as tyrosyl-DNA.

What is exciting

Already past pure discovery: Preclinical validation gives a buyer something concrete to reproduce, optimize, or package into an IND-enabling plan.

Oncology remains highly partnerable: Pharma buyers still pay attention when an asset can be tied to biomarkers, combinations, resistance biology, or a defined tumor segment.

The License-Rx pivot is the real unlock: The exciting version is not just the university pitch; it is the focused path: Indication narrowing plus an outsourced translational evidence package

Negatives / diligence concerns

Translation still unproven: Animal or lab data may not predict human performance; tox, PK/PD, CMC, and indication selection still need diligence.

Competitive field may be crowded: Oncology buyers will ask why this is better than existing modalities, combinations, and biomarker strategies already in the clinic.

Risk Flags

  • Human validation and clinical path require diligence.
  • Patent scope and remaining exclusivity need review with counsel.
  • Inventor readiness and licensing terms are not yet verified.

Strategic Pharma Attractiveness

Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Oncology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.

Most logical pharma targets Merck — Checkpoint-franchise adjacency and combination-trial appetite. AstraZeneca — Oncology breadth plus interest in biomarker-defined populations. Roche / Genentech — Diagnostics plus oncology translational machinery.

Development Strategy to Increase PoS

First indication: Oncology

Study design: Biomarker-selected translational efficacy model followed by a small signal-seeking Phase 1b/2a design.

Key experiments Validate the AI-optimized pivot: Indication narrowing plus an outsourced translational evidence package Run independent replication of the core claim with pre-specified success criteria Generate a partner-facing risk register that separates solved, testable, and unresolved risks

Final Recommendation

Proceed with repositioning: Worth a short exclusive option if diligence confirms IP scope and inventor data quality. The most investable version is: Indication narrowing plus an outsourced translational evidence package

Best next experiment: Run the smallest independent study that validates: Prioritize the fastest reimbursable niche and run an IND-enabling package with a specialized CRO.

Best licensing timing: Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.